Current News Today

- Advertisement -

- Advertisement -

Research is going on, but medical officials want answers soon


An unusual type of blood clot among people who have received the AstraZeneca coronavirus vaccine is puzzling health officials in Europe. The UK now reports 30 cases, up from five, and no cases among people who received the Pfizer vaccine. There’s no evidence that the blood clots are connected to the AstraZeneca vaccine, the New York Times reports. That wouldn’t worry regulators enough to stop the vaccinations, anyway, because they occur so rarely—in Britain, one AstraZeneca recipient in 600,000 has had a blood clot. Still, drug agencies for the UK and European Union, whose regulator will meet next week, are investigating the issue. The unusual nature of the clots is that they’re often accompanied by a drop in blood platelets, which can bring heavy bleeding.

Some health officials in Europe are suspicious and tired of not knowing more, per the Times of Israel. “We have to stop speculating whether there is a link or not,” said the leader of a team reviewing cases in Oslo. “All of these cases had these symptoms three to 10 days after the AstraZeneca inoculation. We did not find any other triggering factor.” Norway’s drug regulator said a link is probable. Britain’s agency said Friday night that seven people have died of clots after receiving the AstraZeneca vaccine but nonetheless renewed its recommendation to take it. Four recipients in France have died, and the government now limits the vaccine’s use to people over 55, per the AP. The family of a 38-year-old woman who died after suffering brain clots filed a complaint Saturday demanding a manslaughter investigation. (Read more AstraZeneca stories.)

Read More:Research is going on, but medical officials want answers soon

Get real time updates directly on you device, subscribe now.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Get more stuff like this
in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.